Shares of Sanofi SA (ADR) (SNY) continue their downward journey since Chris Viehbacher was ousted from his position as CEO late October by the company's board of directors in the coup led by Chairman Serge Weinberg.
Sanofi SA (ADR) (NYSE:SNY), which has recently been in the limelight for the much publicized ousting of its former CEO Christopher Viehbacher, expressed confidence in its drug pipeline in a statement today.
[PRNewswire] Sanofi SA (ADR) (NYSE:SNY) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone Intradermal Quadrivalent vaccine.
(ADR) (FUJIY) to step forward with their respective anti-Ebola treatment therapies. The Ebola outbreak has claimed about 3,500 lives as of October 8. This might have brought out the pharmaceutical industry's human side.
Sanofi SA (ADR) (SNY) responded to allegations of bribery activity in the Middle East and Africa late Monday, stating that it has notified relevant US authorities about the issue and is conducting a private investigation into the matter.